Help build the future of drug safety monitoring

Drug-induced toxicity remains one of the biggest causes of drug-development delay, clinical failure and patient harm. Current monitoring is often insensitive, organ-specific and reliant on damage becoming clinically apparent. We think there is a better way.

Tagomics is a Cambridge-based biotechnology company developing a next-generation multi-omic biomarker platform. Originating from pioneering research by Dr Robert Neely and colleagues at the University of Birmingham, our proprietary technology captures epigenetic features from circulating cell-free DNA that, when combined with advanced bioinformatics, let us detect and localise tissue injury across multiple organs, giving drug developers earlier and more biologically precise insight into treatment-related toxicity.

With successful proof-of-concept programmes behind us and pharmaceutical partners already engaged, we are building towards our first commercial products at Babraham Research Campus.

Read our recent scientific paper:
https://www.cell.com/cell-reports-methods/fulltext/S2667-2375(25)00223-1

The role

This is a hands-on principal scientist role, not a management-only role. You will spend most of your time (around 70%) doing the science yourself: developing methods, writing code and working directly with the data. The rest of your time will be working with partners, team leadership and technical strategy.

You will be the most technically experienced bioinformatician on the drug safety programme. You will line-manage two senior bioinformaticians who are already strong practitioners, so we need someone with the depth to review their methods, support their technical development, and be someone they can bring difficult problems to.

You will also be key to our work with pharmaceutical partners. That means helping to design studies with them, explaining what the data can and can't tell them, and presenting results in a way that supports their decisions.